Cargando…
Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
BACKGROUND: ErbB2/HER2 oncoprotein often drives breast cancers (BCs) which are treated with the anti-ErbB2 antibody trastuzumab. The efficacy of trastuzumab-based metastatic BC therapies is routinely assessed by imaging studies. Trastuzumab typically becomes ineffective in the case of this disease a...
Autores principales: | Durcker, Arik, Yoo, Byong Hoon, Khan, Iman Aftab, Choi, Dongsic, Montermini, Laura, Liu, Xiaoyang, Jovanovic, Sanja, Younis, Tallal, Rosen, Kirill V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541295/ https://www.ncbi.nlm.nih.gov/pubmed/33023655 http://dx.doi.org/10.1186/s13058-020-01342-2 |
Ejemplares similares
-
Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
por: Drucker, Arik, et al.
Publicado: (2020) -
ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth
por: Khan, Iman Aftab, et al.
Publicado: (2018) -
Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
por: Singer, Josef, et al.
Publicado: (2012) -
An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
por: Lu, Qiong, et al.
Publicado: (2016) -
Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody
por: Wang, Chao, et al.
Publicado: (2017)